

# How to Treat and Prevent Arterial Thrombosis with no Increased Bleeding from Accidents, Surgical Perations and other Invasive Procedures

Mark I M Noble

Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK.

## Corresponding author

Mark I M Noble, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK, E-mail: mimnoble@mac.com.

Submitted: 14 June 2017; Accepted: 24 June 2017; Published: 15 July 2017

## Abstract

*An enquiry into the lack of attention awarded to serotonin antagonism in the treatment of arterial thrombosis revealed that the mode of action of serotonin and its platelet receptor antagonists was upon thrombus growth, and not, as with anti-platelet drugs, upon the initiation of thrombosis at sites of damaged endothelium. This lack of effect could explain why this approach has been considered not to be effective. However under conditions of arterial stenosis in which there is platelet activation by increased shear stress, and during the growth phase of arterial thrombi, serotonin 5HT<sub>2A</sub> antagonism has been demonstrated to have great potency in dispersing thrombotic obstruction to blood flow. This mode of action, the lack of participation of serotonin in haemostasis, and the absence of serotonin in wounds accounts for the proven lack of effect of effect of pure specific 5HT<sub>2A</sub> antagonists (i.e., not ones with other actions) on operative bleeding and skin bleeding times. This lack of effect on haemostasis solves the dosing problem encountered by other anti-thrombotic drugs, with which drug concentration cannot be controlled with single fixed doses, leading to the association between increased anti-thrombotic efficacy and increased bleeding complications. Thus 5HT<sub>2A</sub> antagonism appears to be the preferred approach, from the point of view of safety and lack of bleeding risk, to thrombosis therapy in the context of traumatic accidents, surgical operations and invasive procedures such as angioplasty.*

## Introduction

The importance of control of intra-arterial thrombosis is enhanced if this process proves crucial to the development of atherothrombosis as well as to the terminal stages [1,2]. It is commonly thought that thrombosis and haemostasis are always linked, leading to the concept that anti-thrombotic therapy is inevitably associated with excess bleeding, also called 'bleeding risk' [3]. It is true that experience with anticoagulants, which inhibit the action of thrombin, either directly or via the coagulation cascade, and with anti-platelet agents, which inhibit the thromboxane, purine or glycoprotein receptors, has confirmed the bleeding risk with these approaches [4]. At the present time, no alternative approach has been accepted, but in the case of anti-thrombotic treatment of arterial thrombosis, in which thrombin antagonism is ineffective (Belcher et al, 1996) an alternative approach is available, namely inhibition of the serotonin receptor [5-10]. This follows the recommendation of Goto (2004), that drugs which block events upstream of the final common pathway might be better antiplatelet agents than those that merely inhibit platelet aggregation [11].

## The anti-serotonin approach

Serotonin (5-hydroxytryptamine, 5HT) is present in high concentration in blood platelets. In contrast to the thromboxane, purine or glycoprotein mediators serotonin does not influence the formation of haemostatic layers, although it is implicated in shear-induced aggregation and thrombus propagation by positive

feedback from the large amount of intra-platelet serotonin. It is important to distinguish between the serotonergic receptor subtypes [12]. 5HT<sub>1</sub> receptors respond with endothelium dependent nitric oxide mediated vasodilatation, 5HT<sub>2</sub> receptors activate platelets and mediate smooth muscle contraction. Thus in arterial lesions in which vascular smooth muscle is bared, vasoconstriction exacerbates arterial occlusion by thrombus; relief of such vasoconstriction by 5HT<sub>2A</sub> antagonists is a bonus. However, surprisingly to date, serotonin antagonism has not progressed to clinical application. Platelets are the richest source of serotonin in the body outside the brain. Platelets acquire serotonin from the plasma by means of the cell membrane serotonin uptake mechanism, and store the serotonin in dense granules. Inhibition of this mechanism by serotonin reuptake inhibitors (SSRIs) causes depletion of platelet serotonin [13].

## Serotonin dependence of acute arterial thrombosis and its inhibition by 5HT<sub>2A</sub> antagonism

Upon platelet activation (especially with high shear) high concentrations of serotonin in the platelets are released from the dense granules, and act upon platelet serotonin 5HT<sub>2A</sub> receptors to activate more platelets, thus constituting a positive feedback mechanism leading to thrombus growth [14,15]. The serotonin theory supposes that this serotonin mediation is essential for thrombotic occlusion of diseased coronary arteries, owing to the fact that such occlusions are abolished by antagonism of the platelet

5HT<sub>2A</sub> receptor even when the major stimulus of adrenaline is applied and also in the circumstances where thrombolysis has failed to clear a complete thrombotic occlusion [8,9,16,17].

Examination of patients undergoing angiography has showed that a high plasma serotonin level was significantly associated with coronary artery disease in patients younger than 70. In nearly four years of follow up high serotonin levels were also associated with cardiac events. This association persisted after adjustment for conventional risk factor [18]. Unfortunately, most of the antagonists of the platelet serotonin receptor (the 5HT<sub>2A</sub> receptor), have encountered problems, not due to the receptor blockade, that have precluded their application to human arterial thrombosis. However, Th001, Arteclere<sup>TM</sup>, formerly known as IC1170809 or AZ170809, has proved extremely potent as an inhibitor of intracoronary thrombus growth (McAuliffe et al, 1993) and appeared to be safe in a number of trials of toxicity, which are detailed in an Investigator's Brochure. Another important aspect of the McAuliffe results and those of Belcher et al. is that arterial thrombi spontaneously disperse to clear the artery for full blood flow [16,19]. The possibility that the antagonists have a lytic effect was disproved by experiments in Aberdeen (unpublished). Indeed clearance of thrombus by thrombolytic drugs such as tPA is followed in dogs by re-occlusion, which 5HT<sub>2A</sub> antagonism prevents [17]. These results are compatible with the anti-thrombolytic effect of serotonin [20]. A potent reason for pharmaceutical groups to promote 5HT<sub>2A</sub> antagonism is the involvement of 5HT<sub>2A</sub> receptors in promoting thrombosis in diabetes, diabetes now reaching epidemic proportions worldwide with cardiovascular complications the leading reason for morbidity and mortality in this common disease [21]. Other 5HT<sub>2A</sub> receptor antagonists have been available in the past that also showed efficacy in acute arterial thrombosis, e.g., ketanserin, ritanserin, LU 49938, MDL11,939, and LY53,857, MDL 28,133A, DV-7028, AT-1015, APD791 [9,17, 22-31]. The 5HT<sub>2A</sub> antagonists presently available are Th001Arteclere<sup>TM</sup>, a specific platelet receptor antagonist and nefazodone, an antidepressant now taken off the market with non-platelet effects and an unknown effect on thrombosis [32]. At present, sarpegrelate seems to be the only 5HT<sub>2A</sub> antagonist in clinical application. It is used in a wide variety of cardiovascular diseases associated with thrombosis, but appears not to have been trialed in acute coronary syndromes [33]. Th001Arteclere<sup>TM</sup> has had considerable exposure in humans, with a clean safety record. Studies of drugs with mixed receptor subtype antagonist activity we find confusing, e.g., SL65.0472 [10].

#### **Why has the serotonin approach not been followed up?**

This follows from the different mode of action of serotonin and its antagonists, namely activation by increased shear stress and blockade of positive feedback of serotonin generating thrombus growth. Increased shear stress is the very haemodynamic stimulus that occurs in a stenosed artery, and accounts for thrombus formation in both eccentric and concentric coronary artery lesions; 5HT<sub>2A</sub> receptors play a major role in highshear rate thrombus formation [34,35]. When searching for possible antiplatelet drugs, pharmaceutical groups test for platelet aggregability (often in citrated platelet rich plasma in which calcium ions have been removed) and find high aggregability to thromboxane and ADP, together with high potency of their antagonists, compared to little or no activity using serotonin and its antagonists. They thus incorrectly ignore the role of shear stress within stenoses and the involvement of 5HT<sub>2A</sub> receptors in that process and assume that serotonin antagonists are ineffective, even though, in McAuliffe's

1993 study, 170809 showed about ten times the potency of clopidogrel, the leading P<sub>2Y</sub>12 purine (ADP) receptor antagonist, in inhibition of growing thrombus *in vivo*.

A second factor that deterred pharmaceutical groups from the serotonin approach is that the first 5HT<sub>2</sub> antagonist caused multiple problems due to its non 5HT<sub>2A</sub> properties. One of these was alpha1 adrenergic antagonism causing a drop in arterial pressure leading to trial in hypertension, a condition in which serotonin has absolutely no role. The other, more serious, was prolongation of the cardiac action potential and QT interval, causing deaths from arrhythmias. Since that time serotonin antagonists have been rigorously investigated, e.g., Th001, Arteclere<sup>TM</sup>, with the result that there is a clear absence of any cardiac electrophysiological changes attributed to serotonin or Th001Arteclere<sup>TM</sup>.

#### **Superiority of the serotonin approach in haemostasis**

Those performing research on 5HT<sub>2</sub> antagonists since the 1980s when ketanserin became available have observed that the haemostatic layer of blood cells bound to fibrinogen is unaffected. All the early work with these compounds involved experimental surgery on animals, and it was noted that, unlike similar experiments with other anti-thrombotic drugs, there was no excess bleeding, and no oozing coagulopathy. This makes these drugs particularly attractive to surgeons wanting to protect their patients from arterial thrombosis in the peri-operative period [35]. So, is it possible that, contrary to received opinion, the anti-thrombotic activity of 5HT<sub>2A</sub> antagonists can be accompanied by a zero effect on haemostasis. That this can be the case follows from the fact that the anti-thrombotic action only comes into effect during the thrombus growth phase of the occlusive arterial thrombosis process, the lack of participation by serotonin in the haemostatic process and the absence of serotonin in wounds.

Some drugs called 5HT<sub>2A</sub> receptor antagonists have been claimed to prolong bleeding when cutting off the tails of mice or rats, but these need to be confirmed by correct methodologically controlled skin bleeding time measurements in man as performed by Brittenden et al. [26,31,36,37].

#### **Unpublished evidence that a 5HT<sub>2A</sub> antagonist has no effect on haemostasis**

A study carried out at Aberdeen Royal Infirmary, an MHRI approved report in the public domain investigated indices of haemostasis in 48 patients with stable arterial disease [36]. This stability enabled the investigators to design a statistically paired, randomised cross-over trial of placebo versus Th001Arteclere<sup>TM</sup>.

#### **Lack of effect on haemostasis was confirmed as follows:**

Skin bleeding time and a series of ultragra and flow cytometry tests, namely  
Platelet aggregation by Ultragra ASA  
Platelet aggregation by Ultragra Iib/IIIa  
Flow cytometry, resting fibrinogen  
Flow cytometry + 10µM ADP  
Flow cytometry + 1µM ADP  
Flow cytometry + 1µMADP + 10µM 5HT


#### **No significant differences were found in paired statistical tests**

Non compliance did not occur as judged by plasma Th001Arteclere<sup>TM</sup> concentration in the treated arm. Another important aspect of this


study was that the dosing used for the Th001Arteclere™ arm (10mg bd for 2 weeks) was considerably higher than the concentration producing complete arterial clearance in the McAuliffe study. This is important consideration when investigating dosing of other anti-thrombotic drugs.

### The dosing problem with anti-thrombotic therapy

The efficacy of drug action is a function of drug concentration according to the classical concentration-effect.




**Figure 1:** When drugs affect both thrombosis and haemostasis, a single fixed dose regime, e.g., 75mg clopidogrel gives different concentrations for different body masses. A large patient may be inadequately treated whereas a small patient may have bleeding complications.



A lucky patient may receive a dose giving the correct concentration, but only by chance.

**Figure 2:** Patients' sensitivities to a given drug concentration varies. A patient with the blue concentration-effect curve will be inadequately treated, whereas one with the green relationship will have high bleeding risk. A lucky patient may receive a dose giving the correct concentration, but only by chance.



The ideal solution is to use a pure selective 5HT<sub>2A</sub> antagonist such as Th001, Arteclere™ which only affects thrombosis and not haemostasis; then one can give a high dose (right hand arrow in Figure 2), that is safe for all patient weights and sensitivities.

### Conflict of Interest

The author is a shareholder of Thromboserin Ltd that holds the patents on Th001 (Arteclere™).

### References

- Noble MIM (1995) Thrombosis as a unitary hypothesis of cardiovascular risk. *J Cardiovasc Risk* 2: 177-179.
- Steinhubi SR, Moliterno DJ (2005) the role of the platelet in the pathogenesis of atherothrombosis. *Am J Cardiovasc Drugs* 5: 399-408.
- De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H, et al. (2008) Antiplatelet drugs. *Br J Haematol* 142: 515-528.
- Jennings LK (2009) Mechanisms of platelet activation: need for new strategies to protect against plateletmediated atherothrombosis. *Thromb Haemost* 102: 248-257.
- Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM (1996) Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog. *Clinical Science* 90: 363-368.
- Noble MIM, Drake-Holland AJ (1990) the involvement of serotonin in the formation of thrombi at critical coronary artery stenoses in humans. *Coronary Artery Disease* 1: 675-679.
- Noble MIM, Drake-Holland AJ (1992) the possible role of serotonin 5HT<sub>2</sub> receptor antagonism in cardioprotection. *Netherlands Journal of Medicine* 41: 183-189.
- Noble MIM, Drake-Holland AJ (1994) the role of serotonin 5HT<sub>2</sub> receptor antagonism in the control of coronary artery disease. *Quarterly Journal of Medicine* 87: 11-16.
- Torr S, Noble MIM, Folts JD (1990) Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by the specific serotonin 5HT<sub>2</sub> receptor antagonist ritanserin. *Cardiovascular Research* 24: 465-470.
- Moerland M, Kemme M, Dijkmans A, Bergougnan L, Burrgraaf J (2011) Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans. *J Cardiovascular Pharmacology* 58: 575-780.
- Goto S (2004) Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. *Curr Med Chem cardiovasc Hematol Agents* 2: 149-156.
- Van Nueten JM, Leysen JE, de Clerk F, Vanhoutte PM (1998) Serotonergic receptor subtypes and vascular reactivity. *J Cardiovasc Pharmacol* 4: S564-S574.
- Menys VC, Smith CCT, Lewins P, Farmer RDT, Noble MIM (1996) Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. *Clinical Science* 91: 87-92.
- Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G (1993) 5HT<sub>2</sub>-receptors and serotonin release: their role in human platelet aggregation. *Life Sci* 53: 209-215.
- De Clerck F (1990) The role of serotonin in thrombogenesis. *Clin Physiol Biochem* 3: 40-49.
- Belcher PR, Drake-Holland AJ, Hynd J, Noble MIM (1992) Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. *Cardiovascular Research* 26: 292-296.
- Belcher PR, Drake-Holland AJ, Noble MIM (1994) Antagonism of the platelet 5HT<sub>2</sub> receptor in the presence of thrombolysis. *International Journal of Cardiology* 43: 11-20.
- Vikenes K, Farstad M, Nordrehaug JE (1999) Serotonin is associated with coronary artery disease and cardiac events. *Circulation* 100: 483-489.

19. Millson DS, Jessop CL, Swaisland A, Haworth S, Rushton A, et al. (1992) The effect of a selective 5HT<sub>2</sub> receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers. *Br J Clin Pharmacol* 33: 281-288.
20. Vandeplassche G, Hermans C, Van Dael L, Wouters I, De Clerke F (1993) Interplay between platelet-derived 5HT and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis. *J Cardiovasc Pharmacol* 21: 56-69.
21. Yamada K, Niki H, Nagai H, Nishikawa M, Nakagawa H (2012) Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT<sub>2A</sub> receptors in promoting thrombosis in diabetes. *J Pharmacol Sci* 119: 243-250.
22. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, et al. (1986) Serotonin as a mediator of cyclical flow variation in stenosed canine coronary arteries. *Circulation* 73: 572-578.
23. Kirchengast M, Rubsamen K, Lehmann HD (1993) Inhibition by the combined Ca<sup>2+</sup> and 5-HT<sub>2</sub> receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. *J Cardiovasc Pharmacol* 22: 687-694.
24. Hsieh CP, Sakai K, Bruns GC, Dage RC (1994) Effects of MDL 28,133A, a 5-HT<sub>2</sub> receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. *J Cardiovasc Pharmacol* 24: 761-772.
25. Pawlak D, Pawlak K, Chabielska E, Malyszko J, Takada A, et al. (1998) A potent 5HT receptor (5-HT<sub>2A</sub>) antagonist, DV-7028, delays arterial thrombosis development in rats. *Thromb Res* 90: 259-270.
26. Kihara H, Koganei H, Hirose K, Yamamoto H, Yoshimoto R (2001) Antithrombotic activity of AT-1015, a potent 5-HT<sub>2A</sub> receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. *Eur J Pharmacology* 21: 157-162.
27. Rashid M, Watanobe M, Nakazawa M, Nakamura T, Hattori K, et al. (2001) Assessment of affinity and dissociation of newly synthesized 5-HT<sub>2</sub> antagonist, AT=1015: comparison with other 5-HT<sub>2</sub> antagonists. *Jpn J Pharmacol* 87: 189-194.
28. John W Adams, Juan Ramirez, Yunqing Shi, William Thomsen, John Frazer, et al. (2009) APD791, a novel 5HT<sub>2A</sub> receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. *J Pharmacol Exp Ther* 331: 96-100.
29. Przyklenk K, Frelinger AL, Linden D, Whittaker P, Li Y, Barnard MR, et al. (2010) Targeted inhibition of the serotonin 5HT<sub>2A</sub> receptor improves coronary patency in an in vivo model of recurrent thrombosis. *J Thromb Haemost* 8: 331-340.
30. Xiong Y, Teegarden BR, Choi JS, Strah-Pleyne S, Decaire M, Jayakumar H, Dosa PI, et al. (2010) Discovery and structure-activity relationship of APD791: a highly selective 5HT<sub>2A</sub> receptor inverse agonist for the treatment of arterial thrombosis. *J Med Chem* 53: 4412-4421.
31. Adams JW, Ramirez J, Ortuno D, Shi Y, Thomsen W, et al. (2008) Anti-thrombotic and vascular effects of AR246686, a novel 5-HT<sub>2A</sub> receptor antagonist. *Eur J Pharmacol* 586: 234-243.
32. Sussman N, Ginsberg DL, Bikoff J (2001). Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. *Journal of Clinical Psychiatry* 62: 256-260.
33. Nagatomo T, Rashid M, Abul Muntasir A, Komiyama T (2004) Functions of 5HT<sub>2A</sub> receptor and its antagonists in the cardiovascular system. *Pharmacol Ther* 104: 59-81.
34. Sakariassen KS, Hanson SR, Cadroy Y (2001) Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. *Thromb Res* 104: 149-174.
35. Vincentelly A, Jude B, Belisle S (2006) Antithrombotic therapy in cardiac surgery. *Can J Anaesth* 53: S89-S102
36. Brittenden J, Hillis G, Ford I, Hawksworth G, Anderson J, et al. (2006) Report to University of Aberdeen, Scottish Enterprise Grampian, the Coronary Thrombosis Trust, Tenovus Scotland and Thromboserin Ltd, on project: -NO BLEeding time excess with antiplatelet treatment using thomboserin - the NOBLE-1 study. Aberdeen University Archive 2012.
37. Berry CN, Lorrain J, Lochot S, Delahaye M, Lale A, et al. (2001) Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5HT<sub>1B/5-HT<sub>2A</sub></sub> receptor antagonist. *Thromb Haemost* 85: 521-528.

**Citation:** Mark I M Noble (2017). *How to Treat and Prevent Arterial Thrombosis with no Increased Bleeding from Accidents, Surgical Perations and other Invasive Procedures. Journal of Medical & Clinical Research* 2(3):1-4.

**Copyright:** ©2017 Mark I M Noble. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.